On April 1, 2022 Ferring reported its latest Annual Report which shows the company reported revenues of €2,162 million, +11% at AER, +14% at CER and a record level of Net Income at €290 million up +91% AER (Press release, Ferring, APR 1, 2022, View Source [SID1234611339]). These results reflect the company’s strong and leading position in the field of reproductive medicine and maternal health (RMMH), and its growing presence in other specialty areas of medicine. Ferring sales rebounded strongly following the various impacts of COVID-19 during 2020, most particularly within the RMMH franchise in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sales within RMMH grew at 27% CER and achieved a CAGR over the last 2 years of 11% per year driven by our flagship product Menopur, used in ovarian stimulation for women undergoing assisted reproductive technologies. Sales growth within our other specialty franchises in gastroenterology and urology was more muted with some strong individual product performances somewhat offset by product discontinuations and divestments.

Through sustained focus and initiatives on operational efficiency in recent years, increase in operating expenses was constrained to 2% CER benefiting from increased focus and disciplined allocation of resources. Throughout the year important investments were made in protecting our manufacturing infrastructure and the wider supply chain from the volatility caused by COVID-19.

In line with our strategic ambitions, Ferring continued to prioritise investment in progressing our late-stage opportunities and our mid-term growth opportunities which are critical to our future success and achieved many key regulatory milestones during the year.

The combination of strong sales growth and constrained increase in the cost base resulted a significant increase in operating profit growth of 70% CER to reach €358 million. This improved operating profit drove an increase in net cash flow from operations of 38% AER to reach €450 million, and the company maintains its solid financial base from which to realise its strategic agenda over the next years.

"Despite many challenges, 2021 proved to be a year of remarkable progress for Ferring, and we ended the year in a stronger financial position than ever before", said Dominic Moorhead, Chief Financial Officer at Ferring.

The President of Ferring, Per Falk, also commented "2021 was a record year for the company and we are well poised to deliver on the next phase of our growth agenda as we aim to help people live better lives".

CER – Constant Exchange Rates, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period
AER – Actual Exchange Rates
CAGR – Compound Annual Growth Rate

On April 1, 2022 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported the completion of the patient enrollment for the 600 mg dose cohort from Alligator’s Phase I, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is being developed as a tumor-directed therapy for advanced/metastatic cancer (Press release, Alligator Bioscience, APR 1, 2022, https://alligatorbioscience.se/en/alligator-bioscience-announces-completion-of-600-mg-dose-cohort-for-ator-1017-dose-escalation-and-enrollment-for-900-mg-dose-cohort-commences/ [SID1234611338]). The Phase I study with ATOR-1017 is an open-label, dose escalation study in patients with histologically confirmed, advanced and/or refractory solid cancer (NCT04144842). The primary objective of the study is to investigate the safety and tolerability of ATOR-1017, and to determine the recommended dose for subsequent Phase II studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data indicate that for doses up to 600 mg, there were no significant safety concerns with stable disease as the best tumor response. Patient enrollment and treatment for the highest planned dose cohort, 900 mg, has commenced.

As previously announced in December 2021, results from the early readout for ATOR-1017 showed that the drug candidate has an encouraging safety profile. In this readout, there was no dose-limiting toxicity or severe immune-related adverse events (link to press release).

On April 1, 2022 Artios reported that it will be attending the AACR (Free AACR Whitepaper) in New Orleans from 8 – 12 April (Press release, Artios Pharma, APR 1, 2022, View Source [SID1234611337]). If you wish to meet with the team, please contact Stacy at [email protected]

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Attending will be Niall Martin, (CEO), Abid Ansari (CFO), Tania Dimitrova (CBO) Graeme Smith (CSO) and Jay Majithiya (SP Scientist).

On April 1, 2022 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that on March 31, 2022, the Company completed the resubmission of its Biologics License Application ("BLA") for 131I-omburtamab ("omburtamab") to the FDA (Press release, Y-mAbs Therapeutics, APR 1, 2022, View Source [SID1234611336]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The submission is based on the safety and efficacy results of the pivotal Phase 2 studies 101 and 03-133, which the Company expects to publish later this year.

"I am excited to see the completion of Y-mAbs’ second BLA submission in neuroblastoma. As children treated for high-risk systemic neuroblastoma potentially experience longer systemic remissions, we expect more patients eventually relapsing with brain metastasis and there is currently no effective therapy beyond surgery and radiotherapy available for these patients." stated Thomas Gad, Founder, Chairman and President. "As the father of a long-term high-risk neuroblastoma survivor, treated with a predecessor to DANYELZA for systemic high-risk neuroblastoma, and when relapsing with CNS/leptomeningeal metastasis, treated with omburtamab, I know how important this potentially is for families faced with brain metastasis from high-risk neuroblastoma. Y-mAbs was initially founded with the goal of potentially getting both these drugs approved in order to make a major impact on families all over the world."

Dr. Claus Moller, Chief Executive Officer, continued, "We believe omburtamab can potentially address a significant unmet medical need for children with CNS/leptomeningeal metastasis from neuroblastoma, and we look forward to working with the FDA to bring omburtamab to the appropriate patients. This is a key milestone for families and patients facing CNS/leptomeningeal metastasis from neuroblastoma and for Y-mAbs."

Researchers at Memorial Sloan Kettering Cancer Center ("MSK") developed omburtamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests related to the compound.

On April 1, 2022 Boston Scientific Corporation (NYSE:BSX) reported that it will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022, at 8:00 a.m. EDT (Press release, Boston Scientific, APR 1, 2022, View Source [SID1234611334]). The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 27 prior to the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.